Moderna
MRNA
$102.00
Share price
-1.39%
Change (1 day)
-29.15%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
P/S ratio for Moderna (MRNA)
P/S ratio as of April 2024 (TTM): 5.86
According to Moderna 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.86395. At the end of 2023 the company had a P/S ratio of 5.61.
P/S ratio history for Moderna from 2018 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 5.61 | 53.56% |
| 2022 | 3.66 | -37.03% |
| 2021 | 5.81 | -96.15% |
| 2020 | 151 | 9.95% |
| 2019 | 137 | 235.08% |
| 2018 | 40.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.75 | -36.04% | 🇺🇸 USA |
 Novartis NVS | 3.73 | -36.39% | 🇨🇭 Switzerland |
 Merck MRK | 5.28 | -9.91% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | N/A | N/A | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Athersys ATHX | 10.4 | 77.61% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 10.1 | 71.40% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | 15.4 | 161.93% | 🇺🇸 USA |